353 related articles for article (PubMed ID: 30867302)
1. Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects.
Criscuolo E; Castelli M; Diotti RA; Amato V; Burioni R; Clementi M; Ambrosi A; Mancini N; Clementi N
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867302
[TBL] [Abstract][Full Text] [Related]
2. Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific.
Cairns TM; Huang ZY; Gallagher JR; Lin Y; Lou H; Whitbeck JC; Wald A; Cohen GH; Eisenberg RJ
J Virol; 2015 Sep; 89(18):9213-31. PubMed ID: 26109729
[TBL] [Abstract][Full Text] [Related]
3. Glycoprotein C of Herpes Simplex Virus 1 Shields Glycoprotein B from Antibody Neutralization.
Komala Sari T; Gianopulos KA; Nicola AV
J Virol; 2020 Feb; 94(5):. PubMed ID: 31826995
[TBL] [Abstract][Full Text] [Related]
4. A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus.
Du R; Wang L; Xu H; Wang Z; Zhang T; Wang M; Ning Y; Deng F; Hu Z; Wang H; Li Y
Antiviral Res; 2017 Nov; 147():131-141. PubMed ID: 29061442
[TBL] [Abstract][Full Text] [Related]
5. Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus.
Krawczyk A; Krauss J; Eis-Hübinger AM; Däumer MP; Schwarzenbacher R; Dittmer U; Schneweis KE; Jäger D; Roggendorf M; Arndt MA
J Virol; 2011 Feb; 85(4):1793-803. PubMed ID: 21123390
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
7. A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus.
Ramsey NLM; Visciano M; Hunte R; Loh LN; Burn Aschner C; Jacobs WR; Herold BC
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295919
[TBL] [Abstract][Full Text] [Related]
8. Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E.
Hook LM; Huang J; Jiang M; Hodinka R; Friedman HM
J Virol; 2008 Jul; 82(14):6935-41. PubMed ID: 18480440
[TBL] [Abstract][Full Text] [Related]
9. Correlation between herpes simplex virus neutralizing antibody titers determined by ELVIS cell and traditional plaque reduction assays.
Blevins TP; Yu Y; Belshe RB; Bellamy AR; Morrison LA
PLoS One; 2019; 14(4):e0214467. PubMed ID: 30946751
[TBL] [Abstract][Full Text] [Related]
10. Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans.
Cairns TM; Huang ZY; Whitbeck JC; Ponce de Leon M; Lou H; Wald A; Krummenacher C; Eisenberg RJ; Cohen GH
J Virol; 2014 Nov; 88(21):12612-22. PubMed ID: 25142599
[TBL] [Abstract][Full Text] [Related]
11. Role of Microvesicles in the Spread of Herpes Simplex Virus 1 in Oligodendrocytic Cells.
Bello-Morales R; Praena B; de la Nuez C; Rejas MT; Guerra M; Galán-Ganga M; Izquierdo M; Calvo V; Krummenacher C; López-Guerrero JA
J Virol; 2018 May; 92(10):. PubMed ID: 29514899
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Vesicular Stomatitis Virus Pseudotypes Bearing Essential Entry Glycoproteins gB, gD, gH, and gL of Herpes Simplex Virus 1.
Rogalin HB; Heldwein EE
J Virol; 2016 Nov; 90(22):10321-10328. PubMed ID: 27605677
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro.
Mikloska Z; Sanna PP; Cunningham AL
J Virol; 1999 Jul; 73(7):5934-44. PubMed ID: 10364346
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies to distinct sites on herpes simplex virus (HSV) glycoprotein D block HSV binding to HVEM.
Nicola AV; Ponce de Leon M; Xu R; Hou W; Whitbeck JC; Krummenacher C; Montgomery RI; Spear PG; Eisenberg RJ; Cohen GH
J Virol; 1998 May; 72(5):3595-601. PubMed ID: 9557640
[TBL] [Abstract][Full Text] [Related]
15. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.
Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH
J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201
[TBL] [Abstract][Full Text] [Related]
16. Higher Throughput Quantification of Neutralizing Antibody to Herpes Simplex Viruses.
Blevins TP; Mitchell MC; Korom M; Wang H; Yu Y; Morrison LA; Belshe RB
PLoS One; 2015; 10(12):e0144738. PubMed ID: 26658766
[TBL] [Abstract][Full Text] [Related]
17. Neutralizing human recombinant antibodies against herpes simplex virus type 1 glycoproteins B from a phage-displayed scFv antibody library.
Bagheri V; Nejatollahi F; Esmaeili SA; Momtazi AA; Motamedifar M; Sahebkar A
Life Sci; 2017 Jan; 169():1-5. PubMed ID: 27888111
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for the antibody neutralization of herpes simplex virus.
Lee CC; Lin LL; Chan WE; Ko TP; Lai JS; Wang AH
Acta Crystallogr D Biol Crystallogr; 2013 Oct; 69(Pt 10):1935-45. PubMed ID: 24100313
[TBL] [Abstract][Full Text] [Related]
19. Development of an HSV-1 neutralization test with a glycoprotein D specific antibody for measurement of neutralizing antibody titer in human sera.
Luo Y; Xiong D; Li HH; Qiu SP; Lin CL; Chen Q; Huang CH; Yuan Q; Zhang J; Xia NS
Virol J; 2016 Mar; 13():44. PubMed ID: 26987753
[TBL] [Abstract][Full Text] [Related]
20. Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.
Awasthi S; Belshe RB; Friedman HM
J Infect Dis; 2014 Aug; 210(4):571-5. PubMed ID: 24652496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
